Developer docs
API playgroundTry for free, no card

Search company profiles

Lyme Diagnostics

Full company profile

uuid0004kxv

Namestring
Lyme Diagnostics
Legal namestring
Lyme Diagnostics Ltd.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Lyme Diagnostics Ltd. is a Hungary-based private diagnostics company that develops and commercializes DualDur, a proprietary cell technology medium for the laboratory diagnosis of Lyme borreliosis. DualDur conserves patient blood or CSF samples for 2-3 weeks, concentrates Borrelia spirochetes by at least 1,000x, and enables direct visualization of live, motile spirochetes via dark-field microscopy, optionally augmented with an automated AI-based microscopy module for image analysis. The method bypasses immune-response-based serology and genetic-detection methods, which are unreliable in early-stage infection, and has demonstrated 93% sensitivity, 89% specificity, and 96% Positive Predictive Value in clinical trials.

The company serves three primary B2B segments: general practitioners, clinics and laboratories, and trained Lyme disease specialists, with theoretical and practical training delivered as part of the offering. Its go-to-market is enterprise field sales directed at European laboratory and clinic networks, supplemented by the dualdur.com platform for international sample submission from 30+ countries. Revenue is generated through laboratory diagnostic testing services (DualDur investigation, Western-blot confirmation, and clinical symptom assessment) performed at partner facilities. The core technology was developed by Dr. Béla Pál Bózsik over ~30 years, achieved IVD CE registration in 2020 after the largest prospective clinical trial in Europe for Lyme diagnostics (400 subjects, 8 sites, 6 countries), and was cited in the 2018 EU Parliament Lyme Resolution. Non-dilutive funding has come from the EU Horizon 2020 programme (grant agreement No. 805609) and related EISMEA awards.

Short descriptiontext

Lyme Diagnostics Ltd. is a Budapest-based diagnostics company that sells DualDur, an IVD CE-registered cell technology medium and direct-detection method for Lyme borreliosis, serving European GPs, clinics, laboratories, and Lyme disease specialists across 30+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBudakalász, Hungary
HQ citystring
Budakalász
HQ countrystring
Hungary
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Lyme disease diagnostics, in-vitro diagnostic devices, dark-field microscopy, Borrelia spirochete detection, clinical laboratory testing
Industry2 codes
PRIMARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
In-Vitro Diagnostics for Infectious Disease
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Laboratory Diagnostic Testing Services
TypeProfessional Services
Description

The company provides laboratory diagnostic services for Lyme borreliosis using the DualDur method, including clinical symptoms assessment, DualDur investigation, and Western-blot confirmation. Tests are performed at partner laboratories and sent samples from 30+ countries.

lymediagnostics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1DualDur
Description

Cell technology medium and preparation method for direct detection of Borrelia burgdorferi sensu lato spirochetes through dark-field microscopy; available as IVD CE registered medical device

lymediagnostics.com
Core offering1 text field

Lyme Diagnostics Ltd. sells the DualDur cell-technology medium and IVD CE-registered preparation method for laboratory diagnosis of Lyme borreliosis, which conserves and 1,000x-concentrates live Borrelia spirochetes from patient blood for direct visualization via dark-field microscopy. The company bundles this with clinical symptoms assessment, DualDur investigation services, Western-blot confirmation, and theoretical/practical training and continuous support for Lyme specialists at partner laboratories and clinics in Europe.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 93% sensitivity in detecting Lyme borreliosis
+3 more records
Product overview1 text field

Lyme Diagnostics Ltd. offers DualDur as its core in-vitro diagnostic product - a cell technology medium and preparation method for Lyme borreliosis diagnosis. This is supplemented by diagnostic services including clinical symptoms assessment (via questionnaire), DualDur dark-field microscopy investigation, and Western-blot testing for enhanced specificity. The company also provides training and support services for Lyme specialists. DualDur with automated AI microscopy represents their technologically advanced offering, achieving 96% PPV in clinical trials and IVD CE registration for the European market.

Product and service4 records
1DualDur Cell Technology Medium (DualDur diagnostic method)
CategoryIn-vitro diagnostic device (Lyme borreliosis)
Description

IVD CE-registered cell technology medium and preparation method that conserves and 1,000x-concentrates live Borrelia spirochetes from a patient's blood sample (or CSF) for direct visualization via dark-field microscopy, enabling Lyme borreliosis diagnosis at any disease stage independent of immune response.

2Clinical Symptoms Assessment
CategoryDiagnostic service
Description

Questionnaire-based service in which a trained professional records the clinical symptoms reported by the patient to support Lyme borreliosis diagnosis alongside DualDur and Western-blot testing.

3Western-blot Confirmation Testing
CategoryDiagnostic service
Description

Standard and modified Western-blot tests performed to enhance specificity and confirm the type of spirochete, helping prescribe appropriate treatment.

4Lyme Specialist Training and Support
CategoryTraining and support service
Description

Theoretical and practical training program for Lyme specialists on how to use the DualDur system for best diagnosis, supplemented by continuous support from Lyme Diagnostics.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Multi-country clinical trial conducted at 8 sites across 6 Central European countries: Hungary (Istenhegyi Genetic Diagnostics Centre), Austria (MedUni Vienna), Czechia (FORBELI s.r.o.), Germany (Praxis Dr.med Reinhardt), Poland (St. Luke's Clinic, Centrum Dr. Ozimek), Slovakia (Borélia centrum Bratislava, BCB Clinic). Laboratory investigations were carried out at Synlab laboratories in Hungary.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

The Hungarian competent authority that managed the IVD CE registration and clinical research of DualDur, including performance assessment through in-vitro studies, clinical trials for stability and detectability, and artifact generation studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner laboratory that carried out the laboratory investigations for the EU clinical trial of DualDur, processing samples from multiple clinical sites across Central Europe.

4dualdur.com
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner platform through which DualDur testing services are made available to customers internationally, expanding access beyond the European laboratory network.

lymediagnostics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global IVD leader offering Vidas and BioBall serology panels for Lyme disease. Comparable as an established diagnostics player serving European clinical laboratories with Lyme tests, though bioMérieux's offering is serology-based rather than direct detection.

TypeBroad incumbent
Description

Specialty IVD company with the Liaison platform for infectious disease serology including Lyme. Comparable as a European-headquartered diagnostics manufacturer selling Lyme immunoassays into the same lab channel that Lyme Diagnostics targets.

TypeBroad incumbent
Description

Major European specialty serology provider including comprehensive Lyme Western blot and ELISA menus. Comparable as a competitor in the Lyme diagnostics workflow at the same clinical laboratory channel, backed by PerkinElmer's broader life sciences platform.

TypeBroad incumbent
Description

Global molecular diagnostics and sample-preparation leader with PCR-based Lyme and tick-borne disease tests. Comparable as a competing modality (molecular vs. microscopy) for direct Lyme detection, serving the same reference lab customer base.

TypeBroad incumbent
Description

Cobas/Elecsys-based Lyme serology is widely deployed across European hospital networks. Comparable as the entrenched standard-of-care serology incumbent that Lyme Diagnostics' direct-detection method is positioned to complement or displace for ambiguous cases.

6Abbott Diagnostics
TypeBroad incumbent
Description

Architect and Alinity platforms include Lyme serology assays deployed across European laboratories. Comparable as a deep-pocketed established IVD competitor serving the same clinical lab and hospital channel.

7IGeneX
TypeDirect peer
Description

US-based specialty reference laboratory offering PCR and immunoblot-based Lyme and tick-borne disease testing. Comparable as a specialized Lyme diagnostics lab targeting complex and chronic-Lyme cases, competing for the same physician-referred testing volume through direct sample shipment.

TypeEmerging player
Description

Specialty reference lab focused on Bartonella and tick-borne disease direct detection using culture and PCR. Comparable as a niche direct-detection player in the same Lyme and co-infection specialty testing market that Lyme Diagnostics addresses.

TypeEmerging player
Description

Developer of Nanotrap antigen-detection technology for Lyme and other infectious diseases. Comparable as an emerging direct-detection Lyme diagnostics company pursuing a different concentration/capture technology (nanoparticles vs. DualDur medium) but serving the same unmet clinical need.

TypeEmerging player
Description

T cell-based specialty diagnostics company expanding into Lyme after T-SPOT tuberculosis franchise. Comparable as a specialty immunodiagnostics player with European regulatory footprint targeting infectious disease direct-detection use cases overlapping with Lyme Diagnostics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lyme Diagnostics

In-Vitro Diagnostics for Infectious Diseaselymediagnostics.com

Lyme Diagnostics Ltd. is a Budapest-based diagnostics company that sells DualDur, an IVD CE-registered cell technology medium and direct-detection method for Lyme borreliosis, serving European GPs, clinics, laboratories, and Lyme disease specialists across 30+ countries.

What Lyme Diagnostics does

Lyme Diagnostics Ltd. is a Hungary-based private diagnostics company that develops and commercializes DualDur, a proprietary cell technology medium for the laboratory diagnosis of Lyme borreliosis. DualDur conserves patient blood or CSF samples for 2-3 weeks, concentrates Borrelia spirochetes by at least 1,000x, and enables direct visualization of live, motile spirochetes via dark-field microscopy, optionally augmented with an automated AI-based microscopy module for image analysis. The method bypasses immune-response-based serology and genetic-detection methods, which are unreliable in early-stage infection, and has demonstrated 93% sensitivity, 89% specificity, and 96% Positive Predictive Value in clinical trials.

The company serves three primary B2B segments: general practitioners, clinics and laboratories, and trained Lyme disease specialists, with theoretical and practical training delivered as part of the offering. Its go-to-market is enterprise field sales directed at European laboratory and clinic networks, supplemented by the dualdur.com platform for international sample submission from 30+ countries. Revenue is generated through laboratory diagnostic testing services (DualDur investigation, Western-blot confirmation, and clinical symptom assessment) performed at partner facilities. The core technology was developed by Dr. Béla Pál Bózsik over ~30 years, achieved IVD CE registration in 2020 after the largest prospective clinical trial in Europe for Lyme diagnostics (400 subjects, 8 sites, 6 countries), and was cited in the 2018 EU Parliament Lyme Resolution. Non-dilutive funding has come from the EU Horizon 2020 programme (grant agreement No. 805609) and related EISMEA awards.

Lyme Diagnostics firmographics

Firmographics
Name
Lyme Diagnostics
Legal name
Lyme Diagnostics Ltd.
Website
https://lymediagnostics.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Lyme Diagnostics Ltd. is a Budapest-based diagnostics company that sells DualDur, an IVD CE-registered cell technology medium and direct-detection method for Lyme borreliosis, serving European GPs, clinics, laboratories, and Lyme disease specialists across 30+ countries.
Ownership category
akta.pro rank

Lyme Diagnostics industry classification

Industry
Product category
In-Vitro Diagnostics for Infectious Disease
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs

Keywords

  • Lyme disease diagnostics
  • In-vitro diagnostic devices
  • Dark-field microscopy
  • Borrelia spirochete detection
  • Clinical laboratory testing

Where Lyme Diagnostics is headquartered

Location

Headquarters

HQ city
Budakalász
HQ country
Hungary
HQ region
Europe

Offices2 records

Markets served

Lyme Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Laboratory Diagnostic Testing Services: The company provides laboratory diagnostic services for Lyme borreliosis using the DualDur method, including clinical symptoms assessment, DualDur investigation, and Western-blot confirmation. Tests are performed at partner laboratories and sent samples from 30+ countries.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Lyme Diagnostics product offering

Product offering

Core offering

Lyme Diagnostics Ltd. sells the DualDur cell-technology medium and IVD CE-registered preparation method for laboratory diagnosis of Lyme borreliosis, which conserves and 1,000x-concentrates live Borrelia spirochetes from patient blood for direct visualization via dark-field microscopy. The company bundles this with clinical symptoms assessment, DualDur investigation services, Western-blot confirmation, and theoretical/practical training and continuous support for Lyme specialists at partner laboratories and clinics in Europe.

Product overview

Lyme Diagnostics Ltd. offers DualDur as its core in-vitro diagnostic product - a cell technology medium and preparation method for Lyme borreliosis diagnosis. This is supplemented by diagnostic services including clinical symptoms assessment (via questionnaire), DualDur dark-field microscopy investigation, and Western-blot testing for enhanced specificity. The company also provides training and support services for Lyme specialists. DualDur with automated AI microscopy represents their technologically advanced offering, achieving 96% PPV in clinical trials and IVD CE registration for the European market.

Differentiator

Problem solved

Functional benefit

Brands

  • DualDur: Cell technology medium and preparation method for direct detection of Borrelia burgdorferi sensu lato spirochetes through dark-field microscopy; available as IVD CE registered medical device

Products and services

  • DualDur Cell Technology Medium (DualDur diagnostic method) IVD CE-registered cell technology medium and preparation method that conserves and 1,000x-concentrates live Borrelia spirochetes from a patient's blood sample (or CSF) for direct visualization via dark-field microscopy, enabling Lyme borreliosis diagnosis at any disease stage independent of immune response.
  • Clinical Symptoms Assessment Questionnaire-based service in which a trained professional records the clinical symptoms reported by the patient to support Lyme borreliosis diagnosis alongside DualDur and Western-blot testing.
  • Western-blot Confirmation Testing Standard and modified Western-blot tests performed to enhance specificity and confirm the type of spirochete, helping prescribe appropriate treatment.
  • Lyme Specialist Training and Support Theoretical and practical training program for Lyme specialists on how to use the DualDur system for best diagnosis, supplemented by continuous support from Lyme Diagnostics.

Quantifiable outcome

  • 93% sensitivity in detecting Lyme borreliosis
  • +3 more outcomes

Companies that use Lyme Diagnostics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Lyme Diagnostics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Lyme Diagnostics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and major.

  • Clinical Trial Sites (Hungary, Austria, Czechia, Germany, Poland, Slovakia)coreStrategic or Co-development Partner · 1 January 2019Multi-country clinical trial conducted at 8 sites across 6 Central European countries: Hungary (Istenhegyi Genetic Diagnostics Centre), Austria (MedUni Vienna), Czechia (FORBELI s.r.o.), Germany (Praxis Dr.med Reinhardt), Poland (St. Luke's Clinic, Centrum Dr. Ozimek), Slovakia (Borélia centrum Bratislava, BCB Clinic). Laboratory investigations were carried out at Synlab laboratories in Hungary.
  • OGYÉI (National Institute of Pharmacy and Nutrition)coreStrategic or Co-development PartnerThe Hungarian competent authority that managed the IVD CE registration and clinical research of DualDur, including performance assessment through in-vitro studies, clinical trials for stability and detectability, and artifact generation studies.
  • Synlab Laboratories HungarycoreStrategic or Co-development PartnerPartner laboratory that carried out the laboratory investigations for the EU clinical trial of DualDur, processing samples from multiple clinical sites across Central Europe.
  • dualdur.commajorChannel Partner/ Reseller/ DistributorDistribution partner platform through which DualDur testing services are made available to customers internationally, expanding access beyond the European laboratory network.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Lyme Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • bioMérieux: Global IVD leader offering Vidas and BioBall serology panels for Lyme disease. Comparable as an established diagnostics player serving European clinical laboratories with Lyme tests, though bioMérieux's offering is serology-based rather than direct detection.
  • DiaSorin: Specialty IVD company with the Liaison platform for infectious disease serology including Lyme. Comparable as a European-headquartered diagnostics manufacturer selling Lyme immunoassays into the same lab channel that Lyme Diagnostics targets.
  • EUROIMMUN (PerkinElmer): Major European specialty serology provider including comprehensive Lyme Western blot and ELISA menus. Comparable as a competitor in the Lyme diagnostics workflow at the same clinical laboratory channel, backed by PerkinElmer's broader life sciences platform.
  • QIAGEN: Global molecular diagnostics and sample-preparation leader with PCR-based Lyme and tick-borne disease tests. Comparable as a competing modality (molecular vs. microscopy) for direct Lyme detection, serving the same reference lab customer base.
  • Roche Diagnostics: Cobas/Elecsys-based Lyme serology is widely deployed across European hospital networks. Comparable as the entrenched standard-of-care serology incumbent that Lyme Diagnostics' direct-detection method is positioned to complement or displace for ambiguous cases.
  • Abbott Diagnostics: Architect and Alinity platforms include Lyme serology assays deployed across European laboratories. Comparable as a deep-pocketed established IVD competitor serving the same clinical lab and hospital channel.

Direct peers

  • IGeneX: US-based specialty reference laboratory offering PCR and immunoblot-based Lyme and tick-borne disease testing. Comparable as a specialized Lyme diagnostics lab targeting complex and chronic-Lyme cases, competing for the same physician-referred testing volume through direct sample shipment.

Emerging players

  • Galaxy Diagnostics: Specialty reference lab focused on Bartonella and tick-borne disease direct detection using culture and PCR. Comparable as a niche direct-detection player in the same Lyme and co-infection specialty testing market that Lyme Diagnostics addresses.
  • Ceres Nanosciences: Developer of Nanotrap antigen-detection technology for Lyme and other infectious diseases. Comparable as an emerging direct-detection Lyme diagnostics company pursuing a different concentration/capture technology (nanoparticles vs. DualDur medium) but serving the same unmet clinical need.
  • Oxford Immunotec: T cell-based specialty diagnostics company expanding into Lyme after T-SPOT tuberculosis franchise. Comparable as a specialty immunodiagnostics player with European regulatory footprint targeting infectious disease direct-detection use cases overlapping with Lyme Diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Lyme Diagnostics social profiles

Digital presence

Lyme Diagnostics compliance and trust

Trust signal

Compliance2 records

Lyme Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lyme Diagnostics leadership team

Management profile

Number of profiles

Profiles3 records

Lyme Diagnostics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lyme Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lyme Diagnostics

What does Lyme Diagnostics do?

Lyme Diagnostics Ltd. sells the DualDur cell-technology medium and IVD CE-registered preparation method for laboratory diagnosis of Lyme borreliosis, which conserves and 1,000x-concentrates live Borrelia spirochetes from patient blood for direct visualization via dark-field microscopy. The company bundles this with clinical symptoms assessment, DualDur investigation services, Western-blot confirmation, and theoretical/practical training and continuous support for Lyme specialists at partner laboratories and clinics in Europe.

Is Lyme Diagnostics a public or private company?

Lyme Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Lyme Diagnostics founded?

Lyme Diagnostics was founded in 2019. It employs 1 to 10 people.

Where is Lyme Diagnostics based?

Lyme Diagnostics is headquartered in Budakalász, Hungary, in the Europe region.

How does Lyme Diagnostics make money?

One revenue line is on record: laboratory Diagnostic Testing Services.

Who are Lyme Diagnostics's main competitors?

Broad incumbents on record are bioMérieux, DiaSorin, EUROIMMUN (PerkinElmer), QIAGEN, Roche Diagnostics and Abbott Diagnostics. IGeneX is listed as a direct peer. Emerging players are Galaxy Diagnostics, Ceres Nanosciences and Oxford Immunotec.

Does Lyme Diagnostics have an API?

No public API is recorded for Lyme Diagnostics.

What industry is Lyme Diagnostics in?

Lyme Diagnostics's product category is In-Vitro Diagnostics for Infectious Disease. Its primary akta.pro industry code is HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays, with a secondary code of HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals